Market intelligence
Fast, evidence-led coverage of the companies and events moving global markets.
All coverage
MORRIS PLAINS, New Jersey, August 28, 2026, 05:58 - Shares in Solstice jumped 17.2% in early trade after the company announced its $14.5 billion…
Market snapshot: August 28, 2026, 05:58 EDT · Corporate announcement: August 27, 2026
| Metric | Latest / guidance | Read-through |
|---|---|---|
| Q2 2026 sales | $1.148B · +11% YoY | Broad demand growth |
| Q2 net income | $119M | Profitable operating base |
| Q2 adjusted EPS | $0.88 | Above $0.77 consensus |
| FY2026 sales guide | $4.125B–$4.185B | Reaffirmed after merger exit |
| FY2026 adjusted EBITDA | $1.035B–$1.055B | 24.8%–25.6% implied margin |
| FY2026 adjusted EPS | $2.75–$2.95 | Unchanged |
| FY2026 capex | $420M–$440M | Heavy investment continues |
| Premarket price / FY2026 EPS midpoint | 23.2× |
| Analyst consensus | Buy · 7 analysts |
| Average 12-month target | $80.43 |
| Target upside from $66 premarket | 21.9% |
| 52-week range | $40.43–$90.80 |
Analyst data checked August 28, 2026. Targets are estimates, not guarantees.
Sources: Solstice Advanced Materials’ August 27 merger-termination release and July 30 results; StockAnalysis premarket screen and analyst summary; Reuters transaction report. Market figures are time-stamped and may change after the open.
Key Tronic Corporation dropped 21.0% to $3.04 ahead of the Friday session. By 05:41 EDT, trading volume stood at roughly 216,000 shares, compared to…
Premarket snapshot: August 28, 2026, 05:41 EDT · Results released August 27, 2026
$10 million of delayed shipments equals 23.8% of current market value.
New program awards exceed the company’s market value by roughly 43%, but they require working capital to ramp.
| Metric | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Revenue | $102.0M | $110.5M |
| GAAP gross margin | 7.8% | 6.2% |
| GAAP net loss | $34.3M | $3.9M |
| Adjusted EPS | −$0.26 | −$0.35 |
Revenue rose 14% sequentially from $89.6 million in Q3.
| Liquidity | Primary risk |
| Q1 guidance | Not issued |
| Backlog | Increasing |
| FY26 revenue | $386.7M |
| Revenue / market cap | 9.2× |
No reliable current analyst consensus is used. The company’s missing Q1 guidance makes financing progress the next measurable signal.
Sources: Key Tronic Q4 FY2026 release; premarket price, volume and market value. Market figures timestamped August 28, 2026, 05:41 EDT. Ratios are calculated from cited figures and rounded.
LogProstyle Inc. fell 30.3% ahead of Friday’s session, erasing gains from a 74.9% surge the day before on takeover news. The swift decline signals…
Known 100% of I-FLATZ; 3,800 target shares.
Known Closing targeted for September.
Not disclosed: purchase price, revenue, EBITDA, assets, debt or expected accretion.
| Metric | Reading | Signal |
|---|---|---|
| Revenue | ¥22.22B | +7.6% |
| Real-estate revenue | ¥20.60B | +9.5% |
| Operating income | ¥1.57B | +17.1% |
| Operating margin | 7.1% | 6.5% prior year |
| Adjusted EBITDA | ¥1.64B | +10.6% |
| Net income | ¥760M | +0.8% |
| Indicator | Reading | Investor read |
|---|---|---|
| Cash | ¥2.28B | Funding buffer |
| Short-term borrowings | ¥1.61B | Refinancing exposure |
| Long-term borrowings | ¥15.54B | Material leverage |
| LogSuite Tokyo revenue | 100% | Kansai diversifies |
| Float | 6.36M shares | Volatility amplifier |
1 Purchase price and financing structure.
2 I-FLATZ revenue, margin, inventory and debt.
3 Integration costs and synergy timetable.
4 Regular-session price discovery after extreme volume.
No reliable current Wall Street consensus coverage was available.
Acquisition announcement · Company financial materials · Premarket movers · SEC filings
Valuation moved before economics arrived.
The deal may not close. Undisclosed consideration, leverage, thin float and integration risk can drive further reversals.
Vistance Networks Inc. shares looked set to fall 42.7% ahead of Friday’s open, largely due to a planned $5 special cash payout, rather than…
$150 million divided by $6.67. This is a scenario, not a forecast; the program does not require purchases.
| Metric | Reading | Change / signal |
|---|---|---|
| Net sales | $319.6M | −1.4% YoY |
| Adjusted EBITDA | $35.8M | −32.1% YoY |
| Core Aurora margin | 14.2% | 24.7% prior year |
| Free cash flow | −$74.7M | Cash use |
| FY EBITDA guidepost | $200M–$225M | Cut by $25M |
| Signal | Reading | Investor test |
|---|---|---|
| Expected year-end cash | $700M–$750M | No outstanding debt expected |
| Expected 2027 tax refund | $160M | Additional optionality |
| Analyst consensus | Hold · 4 ratings | Targets may need adjustment |
| Average target | $14.67 | Verify post-distribution basis |
| Premarket volume | 7,420 | Thin price discovery |
1 Regular-session liquidity should reveal the cleaner post-payment valuation.
2 Repurchase disclosures will show whether authorization becomes actual demand.
3 Aurora’s 14.2% core margin must stabilize against memory costs and stranded expenses.
4 Cash deployment must balance buybacks, organic investment and acquisitions.
$5 special distribution · $150 million buyback increase · Q2 2026 results · OCC contract adjustment
Do not read the raw −42.65% as like-for-like.
The buyback is discretionary. Aurora still faces margin pressure, negative recent free cash flow and post-divestiture execution risk.
BioXcel Therapeutics Inc. dropped nearly 62% ahead of Friday's session following the company's decision to seek Chapter 11 bankruptcy protection. The move changes a…
Chapter 11 turns a pipeline valuation into a recovery waterfall.
Commercial revenue remained small relative to losses. Before court protection, available cash represented roughly 1.5 quarters of the cited operating burn.
CHESAPEAKE, August 28, 2026, 05:04 - Shares in Dollar Tree declined 3.9% following the retailer's projection for third-quarter earnings per share of $0.80 to…
Strong quarter, deliberate Q3 margin reset
*Midpoint of $0.875 versus $1.40 consensus.
Shares of Dollar General Corporation gained 2.5% on Thursday, supported by higher customer traffic, improved margins and an upgraded forecast. The stock ended the…
| Metric | New FY26 view | Previous |
|---|---|---|
| Net-sales growth | 4.0%–4.3% | Lower range |
| Same-store sales | 2.5%–2.9% | 2.2%–2.7% |
| Diluted EPS | $7.80–$8.00 | $7.20–$7.45 |
| Second-half buybacks | Up to $700M | Paused |
| Indicator | Reading | Interpretation |
|---|---|---|
| Customer traffic | +2.0% | Fifth positive quarter |
| Average transaction | +1.5% | Modest basket growth |
| $1 category sales | +16% | Value demand outpaced chain comps |
| Planned $1 assortment | +40% | Holiday 2026 expansion |
Dollar General’s core indicators improved together: traffic, ticket, gross margin and operating profit. The raised outlook and resumed buybacks strengthen the case. The smaller closing gain shows investors are discounting the portion of earnings tied to tariff refunds.
Shares of Okta Inc. jumped 28.6% on Thursday following reports of faster backlog growth and an upgraded annual forecast. The stock ended the session…
| Metric | Q2 FY27 | YoY |
|---|---|---|
| Revenue | $805M | +11% |
| Subscription revenue | $793M | +12% |
| RPO | $4.858B | +17% |
| cRPO | $2.585B | +14% |
| GAAP operating income | $107M | +161% |
| Free cash flow | $227M | +40% |
| Period | Metric | Guidance |
|---|---|---|
| Q3 FY27 | Revenue | $813M–$817M |
| Q3 FY27 | cRPO | $2.590B–$2.600B |
| Q3 FY27 | Operating margin | 24%–25% |
| FY27 | Revenue | $3.216B–$3.226B |
| FY27 | Free cash flow | $910M–$930M |
| FY27 | FCF margin | 28%–29% |
Okta’s rally rests on a measurable combination: faster near-term backlog growth, a doubled GAAP operating margin and 28% free-cash-flow conversion. The stock now prices in continued cRPO expansion and little tolerance for a guidance miss.
Biohaven Ltd. shares fell 4.9% on Thursday after Raymond James cut its price target by 40%. The stock closed at $16.12.
| Firm | Rating | Target | Upside |
|---|---|---|---|
| Raymond James | Strong Buy | $30 | 86% |
| RBC Capital | Outperform | $23 | 43% |
| Asset | Status | Investor signal |
|---|---|---|
| Opakalim / BHV-7000 | Licensed to SK Biopharmaceuticals | Cash now; royalties and milestones later |
| BHV-1300 | Pivotal Graves’ disease study | Late-2027 data is the central readout |
| Remaining pipeline | Clinical-stage | Must justify the $2.43B equity value |
Biohaven exchanged part of opakalim’s long-term upside for immediate balance-sheet strength. The 4.9% decline and above-average volume show investors are recalibrating that trade. The next valuation test is whether BHV-1300 can turn a longer runway into credible pivotal data.
Braskem S.A. ADRs surged 10.8% to hit $1.64 on Thursday. Trading volume soared to 8.04 million shares, significantly higher than the 2.51 million share…
A large supplier-credit headline against a much larger debt problem.
The Petrobras line supports feedstock purchases; it is not a balance-sheet recapitalization.
| Signal | Reading | Investor interpretation |
|---|---|---|
| Market capitalization | ~$283M | Thin equity cushion |
| Enterprise value | ~$12.24B | Debt dominates valuation |
| Trailing net income | −$978M | Equity cannot absorb prolonged losses |
| Operating margin | 0.76% | Little room for feedstock or spread shocks |
| 52-week position | $1.64 vs $1.40–$5.39 | Relief rally near the low |
| Analyst posture | JPM Neutral; Citi Sell; BofA Underperform | Caution predates the new facility |
Petrobras lifted the supplier-credit ceiling by R$2.0 billion and kept 30-day payment terms through December. That improves feedstock continuity during restructuring.
The rally becomes durable only if operating continuity converts into a viable creditor agreement.
SSE Leads FTSE Close as Warsh Lifts Gilt Yields28/08/2026 · 16:47 BST UK EQUITIES · CLOSING READ SSE leads a positive close as gilt…
The NFL has extended its multi-year sportsbook agreements with DraftKings Inc. and Flutter Entertainment plc's FanDuel, and introduced Fanatics, a privately owned company, as…
NFL distribution is secured; unit economics remain the real contest.
Volume and users expanded, but game outcomes and promotions compressed monetization.
The renewal preserved distribution but did not reverse the de-rating.
| Signal | DraftKings | FanDuel parent Flutter | What matters |
|---|---|---|---|
| Q2 revenue | $1.443B, −5% | $4.326B, +3% groupwide | Growth quality diverged |
| Activity | $13.1B sports volume, +15% | FanDuel retains NFL sportsbook status | Access is broad; conversion decides value |
| Profit signal | FY26 EBITDA guide $700M–$900M | Q2 adjusted EBITDA $508M, −45% | Promotions and taxes pressure margins |
| Market close | $24.22, −2.3% | $95.01, −3.1% | Investors remain cautious |
DraftKings and FanDuel retain promotion, real-time statistics, event presence and NFL digital integrations. DraftKings also keeps daily fantasy status. Fanatics joins as a third sportsbook partner and gains online-casino marketing rights.
Positive: payer retention and cross-sell. Negative: customer-friendly results or higher acquisition costs.
Salesforce Inc. rose 22.6% on Thursday, as improved contract growth and increased cash flow boosted investor faith in its AI approach.
AI monetization accelerates; valuation catches up quickly.
| Metric | Value | Growth |
|---|---|---|
| Revenue | $11.35B | +11% |
| cRPO | $33.5B | +14% |
| Agentforce + Data 360 ARR | ≈$3.9B | >+210% |
| Free cash flow | $1.1B | +81% |
| GAAP operating margin | 20.5% | — |
Updated FY2027 revenue range: $46.1B–$46.4B. Contentful and Fin remain pending.
| Rating | Count | Share |
|---|---|---|
| Buy | 29 | |
| Hold | 9 | |
| Sell | 1 |
39 analysts; targets range from $160 to $400. Data viewed Aug. 28, 2026.
| Signal | Bull case | Risk case |
|---|---|---|
| AI monetization | ARR sustains triple-digit growth | Usage fails to lift core growth |
| Guidance quality | Organic raise expands | Acquisitions carry the increase |
| Valuation | Targets move higher | Close already nears consensus |
| Margins | Cash growth stays ahead of sales | Integration costs pressure leverage |
Sources: Salesforce Q2 FY2027 release; Public/Xignite closing data; Google Finance analyst data; Reuters. Prices as of Aug. 27 close. Not investment advice.
Celularity Inc. stock surged over 100% on Thursday, following news of a manufacturing deal that shifted the conversation over the financially challenged cell-therapy firm's…
Potential contract scale meets extreme liquidity and execution risk.
| Measure | USD | Relative scale |
|---|---|---|
| Five-year purchase estimate | >$300M | |
| Closing market value | $60.8M | |
| 2025 revenue | $26.6M | |
| Year-end cash | $6.2M |
The $300M figure is a partner projection, not committed revenue.
Revenue fell 51%; the net loss widened 58%.
Florham Park, New Jersey
9 Grade C + 6 Grade D
projected, not guaranteed
Named products remain unlicensed.
| Signal | Bull case | Risk case |
|---|---|---|
| Commercial conversion | Signed minimum purchases | Forecast remains nonbinding |
| Liquidity | Upfront payments fund scale-up | Equity issuance dilutes holders |
| Manufacturing | Validated lots and release criteria | Qualification delays or batch variability |
| Regulatory | Clear development pathway | No FDA approval for named products |
Sources: Celularity/MuseCell Business Wire release, Aug. 27, 2026; Celularity 2025 Form 10-K; Public/Xignite closing market data. Figures are historical or issuer projections, not investment advice.
Intel Corporation rose 4.36% on Thursday as Nvidia's forecast revived confidence in AI infrastructure spending.
Nvidia's forecast lifted Intel 4.36%; the close remains below Intel's recent $95 share-sale price.
| Company | Close | Move | Volume | Trailing P/E |
|---|---|---|---|---|
| Intel | $92.09 | +4.36% | 100.56M | N/M |
| Nvidia | $227.98 | +8.72% | 298.91M | 28.6× |
| AMD | $476.67 | −0.86% | 16.44M | 122.5× |
| Micron | $935.39 | −0.36% | 28.84M | 21.2× |
The split tape matters: Thursday rewarded Intel's AI exposure, but the whole semiconductor group did not rally.
| Q2 revenue | $16.1B | +25% |
| GAAP gross margin | 40.4% | +12.9 pts |
| GAAP operating margin | 11.1% | +35.8 pts |
| Non-GAAP net income | $2.2B | vs. loss |
| GAAP net result | −$11.0B | loss |
Revenue and margins rose sharply, but the GAAP loss kept earnings quality in focus.
Intel sold 210.5 million shares at $95, creating a clear dilution and execution benchmark.
Nvidia's forecast lifted Intel, yet no new Intel design win was announced.
Intel's 4.36% gain says the market sees value in its exposure to expanding AI budgets. The harder test is conversion: foundry utilization, server share, margin durability and cash generation must justify both a $470 billion valuation and the new capital raised at $95.
Nvidia Holds Slight Gain as Marvell Ends After Hours Lower08/28/2026 · 20:07 EDT NASDAQ AFTER-HOURS · ACTIVE AT RUN START Nvidia holds a slight…
![UK Stock Market Today 28/08/2026 [UPDATE: 16:47 BST] [SSE Leads FTSE Close as Warsh Lifts Gilt Yields]](https://ts2.tech/wp-content/uploads/2026/08/UK-market-dashboard-2026-08-28-1647-1024x683.jpg "UK Stock Market Today 28/08/2026 [UPDATE: 16:47 BST] [SSE Leads FTSE Close as Warsh Lifts Gilt Yields]")
![US Stock Market Today 08/28/2026 [UPDATE: 20:07 EDT] [Nvidia Holds Slight Gain as Marvell Ends After Hours Lower]](https://ts2.tech/wp-content/uploads/2026/08/US-market-dashboard-2026-08-28-2000-1024x683.jpg "US Stock Market Today 08/28/2026 [UPDATE: 20:07 EDT] [Nvidia Holds Slight Gain as Marvell Ends After Hours Lower]")